Lisuride Pharmacology and Treatment of Parkinson’s Disease

Gopinathan, Govindan; Horowski, R.; Suchy, I.

doi:10.1007/978-3-642-73899-9_19

Cited by 12 publications

(2 citation statements)

References 111 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These pharmacological properties may be even more relevant considering that lisuride, like the other dopamine agonists, acts also on the presynaptic dopaminergic autoreceptors, thereby modifying the release of endogenous dopamine. The drug's short half‐life of elimination from the plasma (1.9 + 0.6 hours when given orally in normal volunteers)6 guarantees that autoreceptor stimulation played no major role under our experimental conditions insofar as the long‐lasting effect persisted for days.…”

Section: Discussionmentioning

confidence: 84%

“…The pharmacological effects of lisuride also seem unlikely to arise from its metabolites. These are excreted via the urine and feces in varying proportion, but mainly via the urine as they are with most ergolines 6. In a study conducted by Humpel et al,7 the half‐life for excretion of radio‐labeled material (14[C] lisuride) in elderly volunteers was 10 hours for phase I and 24 hours for phase II.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Long‐duration effect and the postsynaptic compartment: Study using a dopamine agonist with a short half‐life

et al. 2001

View full text Add to dashboard Cite

A possible reason why levodopa induces a sustained, stable motor benefit during the first months to years of therapy may be its long duration of action. This long-duration effect may be due either to a presynaptic storage mechanism or to postsynaptic pharmacodynamic changes. We previously reported that the dopamine agonist ropinirole induced a long-duration response (LDR) in levodopa-naive patients with Parkinson's disease. In this study, we investigated motor responses to the short half-life dopamine agonist lisuride in a group of levodopa naive parkinsonian patients. Once lisuride reached its maximum effect, it was substituted, in randomized order, with placebo. Neither investigators nor patients knew when the active drug was switched to placebo. When patients were switched from lisuride to placebo, their Unified Parkinson's Disease Rating Scale (UPDRS) motor scores and tapping test and screw scores declined to baseline values within a mean 9.0 +/- 1.9 days. The results confirmed that, like ropinirole and levodopa, the short-acting dopamine agonist lisuride induces a long-duration response, probably due to postsynaptic changes.

show abstract

Section: Discussionmentioning

confidence: 84%

Section: Discussionmentioning

confidence: 99%

Long‐duration effect and the postsynaptic compartment: Study using a dopamine agonist with a short half‐life

et al. 2001

View full text Add to dashboard Cite

show abstract

Pleuropulmonary disease associated with dopamine agonist therapy

Bhatt

Keenan

Fleetham

et al. 1991

Annals of Neurology

View full text Add to dashboard Cite

Artificial dopamine agonists are widely employed for the treatment of idiopathic parkinsonism. Pleuropulmonary disease has previously been reported to occur with the use of bromocriptine and mesulergine. We report similar adverse effects induced by the newer agonists lisuride and cabergoline. All these agents are tetracyclic ergot derivatives. This suggests a causal link between ergot-derived dopamine agonists and pleuropulmonary disease.

show abstract

Lisuride: An 8-Alpha-Ergoline with Ergot Antagonistic Properties

Horowski¹

2022

NeuroPsychopharmacotherapy

View full text Add to dashboard Cite

Lisuride Pharmacology and Treatment of Parkinson’s Disease

Cited by 12 publications

References 111 publications

Long‐duration effect and the postsynaptic compartment: Study using a dopamine agonist with a short half‐life

Long‐duration effect and the postsynaptic compartment: Study using a dopamine agonist with a short half‐life

Pleuropulmonary disease associated with dopamine agonist therapy

Lisuride: An 8-Alpha-Ergoline with Ergot Antagonistic Properties

Contact Info

Product

Resources

About